1 Great Dividend to Buy, 1 Weak Dividend to Sell
The following video is part of our "Motley Fool Conversations" series, in which technology editor/analyst Andrew Tonner and health-care editor/analyst David Williamson discuss topics across the investing world.
In this installation of our popular article series, Andrew and David sit down to talk about one dividend stock they like and one worth avoiding. David discusses drug royalty company PDL BioPharma, while Andrew talks about chip making powerhouse Intel. With dividend investing all the rage at present, investors need to know exactly what they're buying before they invest. Listen on to find out which stock deserves some love and you're better off passing on.
Biotech investors are always looking for the next runaway success. Motley Fool co-founder David Gardner has recently identified a small-cap health-care company that he believes is poised for monster returns. To find out which stock is about to reap huge profits from fundamentally changing its industry, download our exclusive special free report "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.
At the time this article was published David Williamson and Andrew Tonner have no positions in the stocks mentioned above. The Motley Fool owns shares of Intel.Motley Fool newsletter services recommendElan. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.